This brief will cover the basics of what PBMs are, what they do, and how they impact the economics of pharmaceuticals
Conclusions GLP-1 was suggested to be an incretin over 32 years ago
Your personalized reports show exactly how your body composition is changing not just what the scale says
Anti-obesity medicines, based around incretin receptor agonists and their novel combination with other appetite regulatory targets, have weight reduction efficacy in this population, addressing obesity-related cardiometabolic complications while preserving skeletal muscle mass
That is what sustainable GLP-1 weight loss actually looks like
There are three GLP-1 FDA decisions expected in early-mid 2026 Eli Lillys Mounjaro with a new indication to reduce the risk of major adverse cardiovascular events (MACE) in patients with T2DM Eli Lillys oral once-daily orforglipron for weight loss Novo Nordisks higher dose (7.2 mg) injectable once-weekly Wegovy for weight loss Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics talented team of clinical experts actively monitors this emerging landscape